For most of medical history, glaucoma surgery was a last resort — reserved for patients whose eye drops and laser treatments had failed, and whose vision was actively at risk. The procedures worked, but they were significant operations. Today, that's no longer the only option.

Microinvasive glaucoma surgery — MIGS — is a category of procedures developed over the last fifteen years that lowers intraocular pressure through tiny, precisely-placed devices or surgical adjustments. The incisions are small. The recovery is short. The risk profile is dramatically better than traditional glaucoma surgery. And for early-to-moderate glaucoma, it has changed the calculus of when and how to intervene.

What glaucoma actually is.

The eye continuously produces a clear fluid called aqueous humor that nourishes its internal structures. That fluid drains out through a microscopic network of channels at the angle where the iris meets the cornea. When the drainage system doesn't work efficiently, pressure inside the eye rises. Over time — usually years — that elevated pressure damages the optic nerve, and that damage causes the gradual, painless vision loss that defines glaucoma.

The treatment goal is therefore simple, even if the disease is not: lower the pressure. Drops do it pharmacologically. Laser treatments do it by improving drainage. MIGS procedures do it surgically — but with a fraction of the disruption of traditional glaucoma operations.

How MIGS works.

MIGS isn't a single procedure. It's a category that includes a growing list of techniques and devices, each designed to enhance fluid drainage from the eye. Some involve tiny stents implanted into the natural drainage pathway. Others use micro-instruments to open or remodel that pathway directly. The OMNI Surgical System, for example, performs a canaloplasty — gently dilating the eye's drainage canal — combined with a controlled goniotomy through a single 1.6mm incision.

What unites these procedures is what they share in common:

For early-to-moderate glaucoma, the question is no longer whether surgery is too aggressive — it's whether continued drops are too passive.

Who benefits most.

MIGS is best suited to patients with mild-to-moderate open-angle glaucoma — by far the most common form of the disease. It's particularly valuable for patients who:

Patients with advanced or aggressive glaucoma, where the optic nerve is significantly damaged or pressure is dangerously high, may still need traditional glaucoma surgery — a trabeculectomy or tube shunt. MIGS isn't a replacement for those operations. It's a new option for the much larger group of patients who never needed the older procedures in the first place.

Combining MIGS with cataract surgery.

Perhaps the most common scenario in my practice is the patient who has both early glaucoma and a developing cataract. Performing MIGS at the same time as cataract surgery has become a standard of care for two reasons.

First, the surgical access is already there. The instruments enter through the same small incisions used for cataract surgery. There's no additional incision, no significant additional operative time, and no separate recovery period.

Second, the combined procedure often produces a meaningful reduction in glaucoma drop burden — sometimes eliminating drops entirely. For patients who've been using daily drops for years, that's a significant quality-of-life improvement.

Insurance generally covers both procedures when medically indicated, and the recovery from a combined cataract-MIGS procedure is essentially identical to cataract surgery alone.

What to expect.

From the patient's perspective, MIGS feels like an extension of cataract surgery rather than a separate event. The procedure is performed under the same topical anesthesia and light sedation. Most patients are home within an hour of arrival. Eye drops are used during the early healing period. Vision recovery follows roughly the same timeline as cataract surgery alone.

The pressure-lowering effect typically becomes apparent within the first weeks and is reassessed at routine post-operative visits. Some patients can stop one or more glaucoma drops; others need fewer drops to achieve the same target pressure. The goal is always individualized: a pressure low enough to protect the optic nerve, achieved with as little medication burden as possible.

A note on timing.

One of the genuine shifts in glaucoma care over the last decade has been a willingness to intervene earlier — before the disease has caused irreversible damage. The historical conservatism about glaucoma surgery existed because the procedures themselves carried real risk. With MIGS, that calculus has changed.

That doesn't mean every glaucoma patient needs surgery, or that MIGS is the right choice for every eye. It does mean that the conversation should happen earlier and more openly than it used to. If you're using glaucoma drops daily, having difficulty with them, or simply curious whether there's a more durable path to pressure control — it's worth a consultation.